Early-stage data are encouraging but from very small sample sizes (2-3 patients per indication) — insufficient to change probability of success estimates materially. Traders should watch for the next multi-dose data readouts in RA (Q3 2026) and SLE (Q4 2026) for CLN-978, and for velinotamig data in Q4 2026 from the China trial, which will provide larger samples and better signal quality.
Price Chart
Executive Summary
Cullinan Therapeutics released clinical data on two T cell engager programs (CLN-978 and velinotamig) for autoimmune diseases, showing early signs of efficacy including remissions in RA and SLE patients. The data are early-stage and from small patient numbers; no formal efficacy endpoint achieved, no approval decisions imminent. The press release is favorable but interim and not yet de-risking the pipeline at scale.
Key Facts
- CLN-978 data from first multi-dose RA cohort: one out of two patients achieved DAS28-ESR remission (score reduced from 4.0 at baseline to 2.2 at week 4, maintained through week 8)
- SLE safety data for first three multi-dose patients described as consistent with prior safety profile; proteinuria improvement supports planned lupus nephritis Phase 2a expansion in early 2027
- Velinotamig data from first two SLE patients: both achieved complete renal response; SLEDAI-2K scores dropped from 16 and 14 at baseline to 0 and 2 at week 8, respectively; no CRS or ICANS observed
- Additional multi-dose data expected for CLN-978 in RA in Q3 2026, SLE in Q4 2026; velinotamig data from Genrix Bio China trial expected in Q4 2026
- Cullinan plans to initiate Phase 1/2a for velinotamig in autoimmune cytopenias (ITP, AIHA) in Q1 2027
Financial Impact
No financial figures disclosed; $810M market cap implies modest near-term commercial value for early-stage programs
Risk Factors
- Small sample sizes (2-3 patients) mean results may not replicate in larger trials
- All data are interim and subject to change with longer follow-up and more patients
- Multiple planned trials require significant capital; dilution risk exists for $810M market cap company
- Competition exists from other CD19/B-cell targeting modalities (CAR-Ts, bispecifics) already in or closer to late-stage development for autoimmune diseases
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3309602 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 1, 2026 25d ago | Press Release | $15.51 | awaiting T+60 | — | $14.72 (−5.09%) |
Sep 24, 2026 4w ago | 8-K | $15.44 | awaiting T+60 | — | $14.72 (−4.66%) |
Sep 24, 2026 4w ago | Press Release | $15.44 | awaiting T+60 | — | $14.72 (−4.66%) |
Sep 22, 2026 4w ago | Institutional Cluster | $21.67 | awaiting T+60 | — | $14.72 (−32.07%) |
Sep 14, 2026 6w ago | 8-K | $20.40 | awaiting T+60 | — | $14.72 (−27.84%) |
Aug 6, 2026 11w ago | 8-K | $17.95 | awaiting T+60 | — | $14.72 (−17.99%) |
Jun 11, 2026 19w ago | Institutional Cluster | $12.98 $21.69 | ▲ +67.10% | ▲ +63.28% | $14.72 (+13.41%) |
Jun 10, 2026 19w ago | Press Release | $12.05 $22.09 | ▲ +83.32% | ▲ +77.15% | $14.72 (+22.16%) |
Jun 8, 2026 20w ago | 8-K | $13.28 $22.33 | ▲ +68.15% | ▲ +64.64% | $14.72 (+10.84%) |
May 19, 2026 23w ago | Press Release | $14.18 $19.64 | ▲ +38.55% | ▲ +32.26% | $14.72 (+3.84%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers